Get the Stockscreener App
113.75
0.30%
-0.365
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $113.75, with a volume of 3.37M.
It is down -0.30% in the last 24 hours and up +4.37% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$114.12
Open:
$113
24h Volume:
3.37M
Relative Volume:
0.39
Market Cap:
$197.70B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
30.60
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-0.70%
1M Performance:
+4.37%
6M Performance:
-13.92%
1Y Performance:
-18.86%
1-Day Range:
$112.62
$114.19
1-Week Range:
$112.62
$116.81
52-Week Range:
$105.27
$139.28
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
113.77 | 198.30B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
382.48 | 148.11B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.88 | 125.95B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
73.69 | 113.10B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.10 | 50.59B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside - TIKR.com
Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus - simplywall.st
Personalized Nutrition Market Size to Reach USD 60.92 Billion by 2035; Expansion is Driven by the Surging Consumer Awareness Related to Preventive Healthcare Globally - GlobeNewswire Inc.
Better Value & Growth: STE, RMD Lead Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock: Is This Quiet Health Tech Giant Your Next Big US Play? - AD HOC NEWS
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial - Law360
Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Share Price Weakness? - simplywall.st
[144] ABBOTT LABORATORIES SEC Filing - Stock Titan
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
NICE recommends leadless pacemakers to treat slow heart rhythms - BioWorld MedTech
Abbott wins FDA approval for updated heart failure monitoring device - MedTech Dive
Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals - ChartMill
Fisher Asset Management LLC Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Laurel Wealth Advisors LLC - MarketBeat
Abbott Laboratories stock forecast for 2030: Exact Sciences acquisition reshapes growth outlook toward $180 - Traders Union
Antibiotics Market - GlobeNewswire Inc.
2 Reasons to Like ABT and 1 to Stay Skeptical - FinancialContent
Rafferty Asset Management LLC Purchases 9,290 Shares of Abbott Laboratories $ABT - MarketBeat
APG Asset Management N.V. Acquires 12,600 Shares of Abbott Laboratories $ABT - MarketBeat
Exact Sciences Vote Clears Path To Abbott Deal And Valuation Recheck - simplywall.st
Harvest Portfolios Group Inc. Raises Stake in Abbott Laboratories $ABT - MarketBeat
Allianz SE Reduces Position in Abbott Laboratories $ABT - MarketBeat
Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Finviz
Abbott Laboratories : next‑generation CardioMEMS™ remote heart failure monitoring reader receives FDA approval to enhance patient experience and help detect disease progression - marketscreener.com
Xponance Inc. Sells 31,276 Shares of Abbott Laboratories $ABT - MarketBeat
Primecap Management Co. CA Sells 65,100 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Erste Asset Management GmbH - MarketBeat
DNB Asset Management AS Reduces Holdings in Abbott Laboratories $ABT - MarketBeat
Aster Capital Management DIFC Ltd Invests $2.92 Million in Abbott Laboratories $ABT - MarketBeat
US IG Wrap — Abbott M&A, utilities lift supply with big March expected - 9fin
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Laboratories Announces $20 Billion Senior Notes Offering - Global Legal Chronicle
Abbott Laboratories Prices $20 Billion Senior Notes Offering - TipRanks
Abbott takes out M&A whopper amid drugs binge - GlobalCapital
Abbott Prices $20 Billion Multi-Tranche Notes to Fund Exact Sciences Deal - TradingView
Assessing Abbott Laboratories (ABT) Valuation After Mixed Share Performance And Conflicting Fair Value Signals - Yahoo Finance
VivaVision Eyes Hong Kong Listing Before Cash Coffers Dry Up - Benzinga
Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now? - Yahoo Finance
Abbott’s US$20b Bond Bet Recasts Growth Story In Oncology Diagnostics - simplywall.st
US Bancorp DE Sells 37,572 Shares of Abbott Laboratories $ABT - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Fox Run Management L.L.C. Invests $1.30 Million in Abbott Laboratories $ABT - MarketBeat
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects - Seeking Alpha
Pre-market: ABT.SW Abbott Laboratories (SIX) -12.00% to CHF88.00: watch CHF85.00 - Meyka
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences - Intellectia AI
Abbott India: Quiet Rally In A Noisy MarketWhat US Investors Miss - AD HOC NEWS
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - AOL.com
Is Abbott Laboratories Stock Underperforming the Nasdaq? - Barchart.com
TD Asset Management Inc Sells 438,522 Shares of Abbott Laboratories $ABT - MarketBeat
Lummis Asset Management LP Sells 14,731 Shares of Abbott Laboratories $ABT - MarketBeat
How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):